Categories

Tag: JPM 2020

The Undercurrents & Subtext of JP Morgan Healthcare 2020 | Luminary Labs, Sara Holoubek

By JESSICA DaMASSA, WTF HEALTH

Sara Holoubek, Founder & CEO of Luminary Labs, a strategy and innovation consultancy — and the recognized “Queen” of identifying the undercurrents and sub-text of conversations at healthcare conferences — dishes about those undercurrents running just-below-the-surface at JP Morgan Healthcare 2020. Where’s the digital health market headed? Says Sara, “When you see too much bottle service at the parties…that’s when you should watch your back!”

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020.

Advice for Health Tech: Focus on Results, Mission, & Critics | Molly Coye, AVIA

By JESSICA DaMASSA, WTF HEALTH

Molly Coye has spent more than two decades working to advance technology initiatives in healthcare, serving roles as diverse as the Commissioner of Health for the State of New Jersey, Chief Innovation Officer for UCLA Health, and now Executive in Residence for AVIA, which mentors more than 50 large health systems on tech selection, adoption, and implementation. With such rich experience working with healthcare incumbents, we asked Molly to size up the current class of innovators, technologists, developers, and investors bringing the latest health tech solutions to market. What have they gotten right? Where do they need to improve? “We’re not so good at cost of care and lack of access,” says Molly, who also sees potential for that to change thanks to the work of organizations like Health Tech for Medicaid and an increased focus on solutions that address the health needs of ALL patient populations.

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020.

Mainstream Adoption of Virtual Care is Like…Online Dating? | Stephany Verstraete, Teladoc Health

By JESSICA DaMASSA, WTF HEALTH

The shift in thinking required to go to a “virtual first” healthcare system may not be as unique to the health industry as we think. Teladoc Health’s new Chief Engagement Officer, Stephany Verstraete, got her start at Match.com — and explains the parallels she sees between the mainstream adoption of telehealth and what she experienced introducing online dating to the masses. Think about it: overcoming skepticism, addressing privacy concerns, and what Stephany says is most important, changing an ingrained behavior — are all challenges currently being faced by virtual care co’s. It’s not a bad idea to flirt with as we talk bigger trends in telehealth engagement.

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020.

Consumer Health Tech Market Outlook for 2020 | Robert Garber, 7Wire Ventures

By JESSICA DaMASSA, WTF HEALTH

7Wire Ventures is a venture fund that invests in early-stage healthcare companies that are focused on connecting with the healthcare consumer — kind of like one of the most successful companies in its portfolio, Livongo, which went public in 2019. Robert Garber, a partner with the firm, stops by to share his point-of-view on where the consumer health tech market will be headed in 2020, if we’ll see more exits, and whether or not consumer health will be able to gain traction with healthcare’s established players like payers and health systems.

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020

Behind the Big Deal: Teladoc Health’s Acquisition of InTouch Health | Joe DeVivo, InTouch Health

By JESSICA DaMASSA, WTF HEALTH

It was a seminal moment in virtual care as Teladoc Health acquired Intouch Health for $600 million, effectively taking its mostly direct-to-consumer telehealth platform directly into more than 2,500 care providers — or, as they say, “from hospital to home.” We caught up with InTouch Health’s CEO, Joe DeVivo, to hear his thoughts on the deal, including what it means for the further advancement of virtual care and for the digital health industry at-large.

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020

What’s Ahead for Livongo & the Health Tech Market in 2020? | Glen Tullman, Livongo

By JESSICA DaMASSA, WTF HEALTH

What does Glen Tullman, Chairman of Livongo, expect from the health tech market in 2020? Livongo may have started a “race for the exits” in digital health with its 2019 IPO, and Glen says he “wants a healthy, consumer-facing digital health market” to help his own business thrive. Does that mean he anticipates more IPOs from the health tech sector this year? We get Glen’s predictions after we catch up on Livongo’s recent moves to partner with DexCom and test a new pathway to reimbursement via Express Scripts’ Digital Health Formulary.

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020.

Taking Healthcare Innovation Beyond the “Peloton Crowd” | Andy Slavitt, Town Hall Ventures

By JESSICA DaMASSA, WTF HEALTH

Andy Slavitt, former Acting Administrator of the Centers for Medicare and Medicaid Services and founder and partner at Town Hall Ventures, talks about how venture capitalists and health tech startups can help make healthcare more affordable and accessible for the 130 million Americans beyond the “Peloton crowd.” We ask Andy if he thinks “social determinants of health” is more than just an industry buzzword, get his advice for startups motivated to make a difference, and hear his predictions for what will change healthcare in this new decade.

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020.

Health in 2 Point 00, Episode 105 | JP Morgan 2020: Virta, Arcadia, Teladoc & more

Today on Health in 2 Point 00, Jess and I bring you the first ever cliffhanger episode—money was flying everywhere during JP Morgan last week, so stay tuned for more tomorrow. Jumping right in, on Episode 105 we discuss Virta Health raising $93 million for diabetes reversal treatment in a super secret way; Blue Mesa getting acquired by Virgin Pulse for diabetes prevention; population health analytics company Arcadia’s $29.5 million raise; Teladoc acquiring InTouch Health for $600 million, and finally Mona Siddiqui leaving the HHS. —Matthew Holt